Fmr LLC Enanta Pharmaceuticals Inc Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Fmr LLC holds 41,462 shares of ENTA stock, worth $468,520. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,462

Previous 39,421 5.18%

Holding current value

$468,520

Previous $688,000 21.95%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$11.43 - $17.02 $23,328 - $34,737	2,041 Added 5.18%	41,462 $537,000
Q1 2024 May 13, 2024	BUY	$10.08 - $17.46 $88,260 - $152,879	8,756 Added 28.55%	39,421 $688,000
Q4 2023 Feb 13, 2024	SELL	$8.18 - $10.78 $34,306 - $45,211	-4,194 Reduced 12.03%	30,665 $288,000
Q3 2023 Nov 13, 2023	SELL	$11.09 - $22.13 $1.17 Million - $2.33 Million	-105,399 Reduced 75.15%	34,859 $389,000
Q2 2023 Aug 11, 2023	BUY	$20.68 - $39.85 $416,846 - $803,256	20,157 Added 16.78%	140,258 $3 Million
Q1 2023 May 11, 2023	SELL	$38.82 - $54.59 $5.62 Million - $7.9 Million	-144,642 Reduced 54.63%	120,101 $4.86 Million
Q4 2022 Feb 13, 2023	SELL	$40.77 - $53.73 $1.87 Million - $2.47 Million	-45,952 Reduced 14.79%	264,743 $12.3 Million
Q3 2022 Nov 10, 2022	SELL	$48.29 - $71.27 $1.91 Million - $2.83 Million	-39,638 Reduced 11.31%	310,695 $16.1 Million
Q2 2022 Aug 12, 2022	BUY	$38.13 - $76.93 $4.12 Million - $8.32 Million	108,161 Added 44.66%	350,333 $16.6 Million
Q1 2022 May 13, 2022	BUY	$56.06 - $74.11 $13.6 Million - $17.9 Million	242,160 Added 2018000.0%	242,172 $17.2 Million
Q2 2021 Aug 13, 2021	BUY	$43.76 - $53.11 $525 - $637	12 New	12 $0

Others Institutions Holding ENTA

# of Institutions

Shares Held

21.2M

Call Options Held

10.4K

Put Options Held

2.3K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $234M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account